Novo Nordisk A/S Hemophilia-A Treatment Wins EU Panel Backing
Published: Sep 20, 2013
Novo Nordisk A/S (NOVOB) won backing from a European Union advisory panel for a hemophilia A medicine, a step forward in the Danish company’s plan to expand treatment offerings for the blood-clotting disorder. Turoctocog alfa was recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use, Novo Nordisk said in an e-mailed statement today. The European Commission, the EU’s executive arm, usually follows the panel’s recommendation.
Help employers find you! Check out all the jobs and post your resume.